Improved detection of AmpC β-lactamases in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis using new susceptibility breakpoints for third-generation cephalosporins

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 3, 2011, Pages 423-424

  Tan, Thean Yen ^a   Ng, Lily Siew Yong ^a   He, Jie ^a   Chen, Dorene Mei Mei ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ACCURACY; ANTIBIOTIC SENSITIVITY; BACTERIUM DETECTION; BACTERIUM ISOLATE; BROTH DILUTION; DISK DIFFUSION; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PROTEUS MIRABILIS; SENSITIVITY AND SPECIFICITY;

EID: 79959226280     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.03.008     Document Type: Letter

References (12)

1. Choi S.H., Lee J.E., Park S.J., Lee S.O., Jeong J.Y., Kim M.N., Woo J.H., Kim Y.S. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob. Agents Chemother. 2008, 52:995-1000.
2. Clinical Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing; Ninteenth Informational Supplement. M100-S19 2009, CLSI, Wayne, PA.
3. Clinical Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. M100-S20 2010, CLSI, Wayne, PA.
4. Coudron P.E. Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J. Clin. Microbiol. 2005, 43:4163-4167.
5. Jacoby G.A. AmpC beta-lactamases. Clin. Microbiol. Rev. 2009, 22:161-182.
6. Koh T.H., Sng L.H., Wang G., Hsu L.Y., Lin R.T., Tee N.W. Emerging problems with plasmid-mediated DHA and CMY AmpC beta-lactamases in Enterobacteriaceae in Singapore. Int. J. Antimicrob. Agents 2007, 30:278-280.
7. Lee K., Lee M., Shin J.H., Lee M.H., Kang S.H., Park A.J., Yong D., Chong Y. Prevalence of plasmid-mediated AmpC beta-lactamases in Escherichia coli and Klebsiella pneumoniae in Korea. Microb. Drug Resist. 2006, 12:44-49.
8. Li Y., Li Q., Du Y., Jiang X., Tang J., Wang J., Li G., Jiang Y. Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China. J. Clin. Microbiol. 2008, 46:1317-1321.
9. Pai H., Kang C.I., Byeon J.H., Lee K.D., Park W.B., Kim H.B., Kim E.C., Oh M.D., Choe K.W. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2004, 48:3720-3728.
10. Pitout J.D., Gregson D.B., Church D.L., Laupland K.B. Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg. Infect. Dis. 2007, 13:443-448.
11. Tan T.Y., Ng L.S., He J., Koh T.H., Hsu L.Y. Evaluation of screening methods to detect plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Antimicrob. Agents Chemother. 2009, 53:146-149.
12. Tan T.Y., Ng S.Y., Teo L., Koh Y., Teok C.H. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. J. Clin. Pathol. 2008, 61:642-644.